Monday, April 8, 2019

AUTOIMMUNITY part 71




The CTLA4 (CD152) molecule is an inhibitory receptor expressed by activated T cells that block the co-stimulatory interaction between CD80 or CD86 on the surface  of antigen-presenting cells and CD28 on T cells. It acts by binding CD80/CD86 with greater affinity than CD28. CTLA4 is expressed late in T-cell activation and serves to turn off the activated state. CTLA4-Ig (abatacept) is a recombinant chimera of CTLA4 and the Fc fragment of IgG1. CTLA4-Ig/abatacept is used for the treatment of RA and is active in mouse models of lupus. Clinical trials in SLE patients are in progress

No comments:

Post a Comment